Medtronic Received Regulatory Approval for Cardiac Software
The company secured FDA clearance and CE marks for new mapping and ablation tools to assist heart surgeons.
Updated on Sept. 30, 2026 in Heart Disease
Live Poll
Do you trust that new medical software updates primarily focus on improving patient care?
Medtronic has received FDA clearance and CE marks for its Affera Prism-2 cardiac mapping software and the PulseSelect ProxBox adapter. These tools are designed to assist physicians by providing real-time data during complex cardiac ablation procedures.
Why it matters
These software updates aim to improve procedural precision and reduce the reliance on X-ray imaging during heart surgeries. By offering a more connected experience, the technology seeks to enhance the efficiency and safety of cardiac interventions.
The Affera Prism-2 software utilizes magnetic and impedance-based tracking to map cardiac electrical activity, while the PulseSelect ProxBox adapter provides impedance-based feedback. The PulseSelect PFA system is currently authorized for use in over 60 countries.
The players
Medtronic
Medtronic is a global medical technology company headquartered in Minnesota that develops devices for chronic diseases.
The details
The Affera Prism-2 software allows for three-dimensional mapping of cardiac electrical activity by tracking diagnostic catheters. The PulseSelect ProxBox adapter complements this by monitoring the proximity of catheters to targeted heart tissue during pulsed field ablation.
Timeline
Medtronic concluded its second fiscal quarter on July 31, 2026.
The FDA clearance and CE marks were announced on September 30, 2026.
The Big Picture
This development follows the broader trajectory of the PulseSelect PFA system, which remains a focal point of cardiac electrophysiology innovation. These updates refine the existing ecosystem by bridging technical gaps between diagnostic mapping and active ablation therapies.
Patients undergoing cardiac ablation may experience reduced radiation exposure due to the software's diminished reliance on X-ray imaging. This technology could lead to more precise procedural outcomes and potentially shorter surgical times for those with heart rhythm issues.
The takeaway
These regulatory approvals signal a shift toward more integrated, high-precision tools in the field of cardiac electrophysiology. Physicians can now utilize advanced impedance-based feedback to improve the accuracy of targeted heart tissue ablation.
Further reading
Learn more about advancements in Heart Disease procedures and cardiac care technology.
Live Poll
Do you trust that new medical software updates primarily focus on improving patient care?
